NCT00092222 2026-03-11
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07383649 2026-02-03
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
The Methodist Hospital Research Institute
Phase 2 Not yet recruiting
NCT07138989 2025-08-24
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05011058 2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2 Terminated
NCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT03296553 2022-01-27
Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
National Institute of Cancerología
Phase 2 Completed
NCT01441063 2020-10-27
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00387530 2019-08-02
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
University of California, San Diego
Phase 2 Withdrawn
NCT00562770 2012-07-31
Oral Valganciclovir Versus Valacyclovir
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00917826 2011-08-01
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
HemaQuest Pharmaceuticals Inc.
Phase 2 Terminated
NCT00992732 2011-08-01
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
HemaQuest Pharmaceuticals Inc.
Phase 2 Terminated